Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2023-06-23 Director's Dealing
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2023-06-23 English
FORM 4
Director's Dealing
2023-06-23 English
FORM 4
Director's Dealing
2023-06-23 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 22, 2023, by Cidara Therapeutics, Inc. The content focuses on the submission of matters to a vote of security holders at the 2023 Annual Meeting of Stockholders, including election of directors, ratification of the independent auditor, and advisory approval of executive compensation. It provides detailed voting results for these proposals. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4472 characters, which is sufficient to include detailed voting results, not just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2023-06-23 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter from Cidara Therapeutics, Inc. responding to a comment letter from the SEC staff regarding the company's previously filed Form 10-K for the fiscal year ended December 31, 2022. The letter discusses specific disclosures and financial details from the 10-K, including revenue recognition and contract liabilities. It does not contain the full 10-K report itself but is a correspondence addressing SEC comments on that filing. The document length is about 11,331 characters, which is relatively short for a full annual report and is clearly a response letter. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory correspondence related to a filing, not the filing itself.
2023-05-31 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Cidara Therapeutics, Inc. It reports the issuance of a press release containing financial results for the first quarter ended March 31, 2023. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as an exhibit. The length of the document is 3703 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the full report itself. Therefore, the appropriate classification is Earnings Release (ER), which covers initial announcements of quarterly financial results with key highlights only.
2023-05-11 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.